Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSIL-015
- Development stage
- Preclinical
- Lead developer
- Psilera
- Modality
- Small Molecules
01
Overview
PSIL-015 is a small molecule prodrug being developed by Psilera as part of its neuroplastogen platform. The compound is designed to promote structural and functional neuroplasticity to treat mental health conditions, potentially without the intense hallucinogenic effects typically associated with traditional psychedelic substances. It is currently in the lead optimization stage of preclinical development, with primary research focused on its application in mood-related disorders and alcohol use disorder (AUD). As a prodrug, PSIL-015 is engineered to optimize the delivery, stability, and metabolic profile of its active neuroplastogenic moiety.
Beyond the preview
Go deeper on PSIL-015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSIL-015.